Geoffrey Scott Gilmartin MD
Critical Care Medicine, Pleural Disease
Attending Physician, Beth Israel Deaconess Medical Center Boston, MA Chief Development Officer Proteostasis Therapeutics Cambridge, MA
Join to View Full Profile
330 Brookline AveGZ402Boston, MA 02215
Phone+1 617-667-4120
Fax+1 617-667-1604
Dr. Gilmartin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts General Hospital/BIDMC/Harvard Medical SchoolFellowship, Pulmonary Disease and Critical Care Medicine, 2000 - 2004
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1997 - 2000
The Warren Alpert Medical School of Brown UniversityClass of 1997
Certifications & Licensure
MA State Medical License 1999 - 2026
Publications & Presentations
PubMed
- 878 citationsBenralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomi...J. Mark FitzGerald, Eugene R. Bleecker, Parameswaran Nair, Stephanie Korn, Ken Ohta
Lancet. 2016-10-29 - 796 citationsEfficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a rand...Eugene R. Bleecker, J. Mark FitzGerald, Pascal Chanez, Alberto Papi, Steven F. Weinstein
Lancet. 2016-10-29 - 45 citationsEffect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United StatesJennifer L. Taylor-Cousar, Minoo Niknian, Geoffrey Gilmartin, Joseph M. Pilewski
Journal of Cystic Fibrosis. 2016-01-01
Press Mentions
Summary of Parent Organized NPS Zoom PanelAugust 8th, 2020
Organoid-Based Personalized Medicine Trial Enrollment CompleteFebruary 28th, 2020
Proteostasis Therapeutics and CF Europe Announce Completion of Patient Enrollment for CHOICES, the First-Ever Personalized Medicine-Based Study in Cystic FibrosisFebruary 24th, 2020- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
